

해외 바이오의약품 임상 현황 (2021.1.18~2021.1.24)

한국바이오의약품협회, 2021.1.26.  
출처: ClinicalTrials.gov

○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04690595	Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia	Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia	Biological: BAFFR-CAR T cells	PeproMene Bio, Inc. City of Hope Medical Center	Phase 1	---
NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma Unclassifiable Recurrent Diffuse Large B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Transformed B-Cell Non-Hodgkin Lymphoma	Drug: Carboplatin Drug: Etoposide Drug: Ifosfamide Drug: Polatuzumab Vedotin Biological: Rituximab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	---
NCT04579523	<sup>213</sup> At-OCT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	Plasma Cell Myeloma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Cyclophosphamide Drug: Fludarabine Phosphate Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 1	---
NCT04083170	Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers	Acute Erythroid Leukemia Acute Lymphoblastic Leukemia Acute Megakaryoblastic Leukemia Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hematopoietic and Lymphoid Cell Neoplasm HIV Infection Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts Non-Hodgkin Lymphoma Refractory Anemia	Drug: Fludarabine Drug: Cyclophosphamide Drug: Thiotepa Radiation: Total-Body Irradiation Procedure: Umbilical Cord Blood Transplantation Other: Cellular Therapy	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	---
NCT04665843	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Drug: Atezolizumab Drug: Tiragolumab Drug: Placebo	Hoffmann-La Roche	Phase 2	---
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2	---

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04665843	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Drug: Atezolizumab Drug: Tiragolumab Drug: Placebo	Hoffmann-La Roche	Phase 2	---
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2	---

○ 프랑스 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04703621	The DART Study- Daratumumab Treatment in ITP	ITP	Drug: Daratumumab Injection	Ostfold Hospital Trust Haukeland University Hospital Oslo University Hospital University Hospital, Akershus Henri Mondor University Hospital	Phase 2	---
NCT04665843	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Drug: Atezolizumab Drug: Tiragolumab Drug: Placebo	Hoffmann-La Roche	Phase 2	---
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2	---

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04712344	Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)	Severe COVID-19	Biological: COVID-19 convalescent plasma	University of Erlangen-Nürnberg Medical School	Phase 2	---

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04715217	Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma	Lymphoma, B-Cell	Biological: CD19-CD22 CAR-T cells	Shanxi Province Cancer Hospital Shanghai Ultra-T Immune Therapeutics Co. LTD	Phase 1  Phase 2	---
NCT04143984	Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Drug: Induction chemotherapy Radiation: Carbon-ion radiotherapy Drug: Camrelizumab	Shanghai Proton and Heavy Ion Center	Phase 2	---
NCT04126044	A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS	Pharmacokinetics	Drug: PF-06439535 (CN) Drug: bevacizumab - EU	Pfizer	Phase 1	---
NCT04660799	A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)	Lymphoma, Large B-Cell, Diffuse	Drug: Rituximab IV Drug: Rituximab SC Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Paracetamol Drug: Diphenhydramine hydrochloride or alternative antihistamine	Hoffmann-La Roche	Phase 2	---

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04677660	A Placebo-Controlled Study of TAK-919 in Healthy Japanese Adults (COVID-19)	Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)	Biological: TAK-919 Biological: Placebo	Takeda	Phase 1  Phase 2	---
NCT04648241	Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older	Tick-Borne Encephalitis	Biological: TBE vaccine 0.5 mL Biological: TBE vaccine 0.25 mL	Pfizer	Phase 3	---